Orgovyx is a medicine used to treat advanced prostate cancer. It is taken as a pill once a day. It works by lowering the body's testosterone, a hormone that helps prostate cancer grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Orgovyx (Relugolix) for Prostate Cancer?
Relugolix, sold as Orgovyx, is a daily tablet used to treat advanced prostate cancer in adults. It is a form of androgen deprivation therapy (ADT), often called hormone therapy, which lowers testosterone because most prostate cancers depend on that hormone to grow. Advanced here covers several situations: cancer that has come back after surgery or radiation (often first detected as a rising level of prostate-specific antigen (PSA) in the blood), cancer that has spread beyond the prostate, and cancer too extensive in the prostate area to be treated by surgery or radiation alone. Hormone therapy has long been given mainly as injections of drugs such as leuprolide every few months. Orgovyx offers the same goal in pill form, which suits some people who would rather avoid injections, at the cost of needing to take a tablet every day. Depending on the stage, hormone therapy may be used alone or alongside radiation or other prostate cancer medicines. Relugolix is also one ingredient of Myfembree, a combination tablet with an estrogen and a progestin used by premenopausal women for heavy bleeding from fibroids or for endometriosis pain. That product has a different dose and different safety concerns, and it has its own page.
Most of the body's testosterone is made in the testicles, on instructions that start in the brain. The brain releases a signaling hormone called GnRH (gonadotropin-releasing hormone), which prompts the pituitary gland to release two further hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These tell the testicles to make testosterone. Relugolix blocks the pituitary's receptors for GnRH, so much less LH and FSH are released and testosterone falls to very low levels, known as castrate levels (below 50 ng/dL, compared with a typical starting level of about 400 ng/dL in the main trial). Injectable drugs such as leuprolide reach the same end by a different route: they first overstimulate this pathway, causing a temporary surge in testosterone before it drops over the following weeks. Because relugolix is a blocker, testosterone falls within days without that initial surge. In the main trial, about half of men reached castrate levels by day 4 and nearly all by day 15. Low testosterone can slow or shrink prostate cancer for a long time, but it does not cure it. Many cancers eventually find ways to grow despite low testosterone, which is when other treatments are added.
Orgovyx comes as a 120 mg tablet. Treatment starts with a loading dose of three tablets (360 mg) on the first day, then one tablet once a day at about the same time each day. It can be taken with or without food. Swallow the tablets whole; do not crush or chew them. If a dose is missed, take it as soon as you remember, unless more than 12 hours have passed. In that case, skip it and take the next dose at the usual time rather than doubling up. Longer gaps matter more: if treatment stops for more than 7 days, it is restarted with the three-tablet loading dose, so check with the prescriber before resuming. Because this is a daily pill rather than an injection that lasts for months, steady daily use and timely refills are what keep testosterone suppressed.
Most side effects come from low testosterone itself and resemble those of other forms of hormone therapy. Hot flashes are the most common, affecting about half of people in the main trial. Tiredness, muscle and joint pain, constipation or diarrhea, weight gain, sweating, trouble sleeping, lower sex drive, erection problems and breast enlargement can also occur. Some people notice low mood or depression, which is worth raising with the care team rather than putting up with. Blood tests often show higher blood sugar, higher triglycerides (a type of blood fat), higher liver enzymes or lower hemoglobin (mild anemia). Hormone therapy can affect heart rhythm by lengthening the QT interval, part of the heartbeat's electrical cycle measured on an ECG (electrocardiogram). Contact the care team right away for dizziness or a pounding or racing heartbeat (palpitations). Chest pain, fainting, sudden weakness or numbness on one side of the body, or trouble speaking can signal a heart attack, stroke or dangerous heart rhythm: call 911. Allergic reactions are uncommon but can include angioedema, a swelling of deeper layers of the skin. For hives or a rash, stop the tablets and contact the prescriber promptly. Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing, is an emergency: call 911.
Some medicines change how much relugolix reaches the bloodstream. Drugs that block a transport protein called P-gp, such as the antibiotic erythromycin, can raise relugolix levels and its side effects. The label advises avoiding them; if one is needed, relugolix is taken first and the other drug at least 6 hours later, or relugolix is paused for a short course. Drugs that speed its removal, such as rifampin (an antibiotic used for tuberculosis), can lower levels enough to weaken its effect and may call for a higher dose. The herbal supplement St. John's wort can also interact. Tell the prescriber and pharmacist about every prescription, over-the-counter medicine and supplement before starting or changing anything. Because hormone therapy can affect heart rhythm, the prescriber needs to know about long QT syndrome in you or your family, heart failure, blood salt (electrolyte) imbalances and any other medicines that lengthen the QT interval. Heart attacks and strokes were reported in 2.7% of people taking relugolix in the main trial (the warning signs are under Side Effects), and blood sugar and blood fats often rise, so existing heart disease, diabetes or high cholesterol deserve closer attention during treatment. Relugolix can harm a pregnancy. Men whose partner could become pregnant should use effective contraception during treatment and for 2 weeks after the last dose. It may also reduce fertility, which is worth raising before starting if you may want to father children. Orgovyx is not approved for women. It also changes hormone test results, so tell any clinician or lab that you take it.
Testosterone usually falls within the first days to two weeks. PSA, a blood marker of prostate cancer activity, usually falls over the first weeks to months of treatment. The care team checks PSA periodically to judge how well the cancer is controlled; if it starts rising, they also check testosterone to confirm it is still suppressed. Expect regular blood tests for sugar, blood fats and liver function, and possibly heart tracings (ECGs) and electrolyte checks if heart rhythm is a concern. Some people take hormone therapy for a defined period, for example around radiation treatment, while others take it long term for cancer that has spread. Over months and years, low testosterone can thin bones and reduce muscle, raising the risk of falls and fractures, so bone health and regular exercise are worth planning for early. If the cancer later grows despite low testosterone, hormone therapy is usually continued while other treatments are added. When relugolix is stopped, testosterone gradually returns. In a trial substudy, about half of men had testosterone back to the normal range or their starting level within 90 days, and hormone-related side effects tend to ease as it recovers.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Orgovyx (Relugolix), what you've noticed, or ask the community a question.